Shulph Ink
Therapeutic Strategies to Overcome ALK Resistance in Cancer
Therapeutic Strategies to Overcome ALK Resistance in Cancer
YOU SAVE £18.56
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at £2.39. Subject to product weight & dimension
Couldn't load pickup availability
Excellent- More about Therapeutic Strategies to Overcome ALK Resistance in Cancer
Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, discusses current strategies to improve and prolong clinical benefit in ALK-driven cancers, including resistance mechanisms and novel therapeutic approaches. It is a valuable resource for cancer researchers, clinicians, and biomedical field members.
Format: Hardback
Length: 216 pages
Publication date: 14 January 2021
Publisher: Elsevier Science Publishing Co Inc
Therapeutic Strategies to Overcome ALK Resistance in Cancer,Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians, and several members of the biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
Therapeutic Strategies to Overcome ALK Resistance in Cancer,Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians, and several members of the biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
Weight: 590g
Dimension: 242 x 266 x 18 (mm)
ISBN-13: 9780128217740
This item can be found in:
UK and International shipping information
UK and International shipping information
UK Delivery and returns information:
- Delivery within 2 - 3 days when ordering in the UK.
- Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
- Returns policy: Return within 30 days of receipt for full refund.
International deliveries:
Shulph Ink now ships to Australia, Belgium, Canada, France, Germany, Ireland, Italy, India, Luxembourg Saudi Arabia, Singapore, Spain, Netherlands, New Zealand, United Arab Emirates, United States of America.
- Delivery times: within 5 - 10 days for international orders.
- Shipping fee: charges vary for overseas orders. Only tracked services are available for most international orders. Some countries have untracked shipping options.
- Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
